Schonfeld Strategic Advisors LLC Trims Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Schonfeld Strategic Advisors LLC trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,440 shares of the medical equipment provider’s stock after selling 835 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in Zimmer Biomet were worth $363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Perbak Capital Partners LLP purchased a new position in Zimmer Biomet in the 4th quarter valued at $558,000. Lido Advisors LLC grew its position in Zimmer Biomet by 6.5% in the 4th quarter. Lido Advisors LLC now owns 23,789 shares of the medical equipment provider’s stock valued at $2,519,000 after buying an additional 1,448 shares during the last quarter. Northern Trust Corp grew its position in Zimmer Biomet by 7.6% in the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider’s stock valued at $250,367,000 after buying an additional 167,435 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Zimmer Biomet by 6.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 322,508 shares of the medical equipment provider’s stock valued at $34,067,000 after buying an additional 19,485 shares during the last quarter. Finally, Quarry LP grew its position in Zimmer Biomet by 518.2% in the 4th quarter. Quarry LP now owns 680 shares of the medical equipment provider’s stock valued at $72,000 after buying an additional 570 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Tuesday, May 6th. Barclays lowered their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Morgan Stanley lowered their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their price target on shares of Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $114.15.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $95.22 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.92 and a 12-month high of $122.25. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company’s 50-day moving average is $104.43 and its two-hundred day moving average is $106.13. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $1.94 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. Zimmer Biomet’s payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.